Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;22(8):1-7.
doi: 10.2174/1871526522666220408110135.

COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: A Proposed Classification and Treatment Strategies

Namit Kant Singh  1 , Neemu Hage  1 , Balaji Ramamourthy  1 , Krishna Medha Kappagantu  1
Affiliations

COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: A Proposed Classification and Treatment Strategies

Namit Kant Singh et al. Infect Disord Drug Targets. 2022.

Abstract

Objectives: Mucormycosis is a rare fungal disease, which was known to affect only immunocompromised hosts, but during the COVID-19 pandemic, a surge in the cases of rhino- orbital-cerebral mucormycosis have been reported; however, the cause is still unknown. As the disease was a rare entity, there was no classification considering the spread and proper management at various stages.

Methods: Extensive literature search with the terms "mucormycosis," "invasive fungal sinusitis," "COVID-19 associated mucormycosis," and "mucormycosis in COVID-19" was conducted on Pubmed, Scopus, and Embase database, taking into consideration case histories, revealing the site of involvement and treatment based on the disease's extent.

Results: Relevant articles were analyzed, and it was found that there is no specific classification of the disease entity and no proper surgical and medical management guidelines to date, Conclusion: This review is an attempt to elaborate on the pathophysiology of mucormycosis and its spread and propose a classification that will help determine policies for the control and prevention of complications, morbidity, and mortality.

Keywords: COVID-19; GRP 78; Mucormycosis; angio-invasion; mucorales; mucoricin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Petrikkos G.; Skiada A.; Lortholary O.; Roilides E.; Walsh T.J.; Kontoyiannis D.P.; Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012,54(Suppl. 1),S23-S34 - DOI - PubMed
    1. Hassan M.I.A.; Voigt K.; Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol 2019,57(Suppl. 2),S245-S256 - DOI - PubMed
    1. Ibrahim A.S.; Spellberg B.J.; Avenissian V.; Fu Y.; Filler S.G.; Edwards J.E.J.; Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 2005,73(2),999-1005 - DOI - PubMed
    1. Ribes J.A.; Vanover-Sams C.L.; Baker D.J.; Zygomycetes in human disease. Clin Microbiol Rev 2000,13(2),236-301 - DOI - PubMed
    1. Lewis R.E.; Kontoyiannis D.P.; Epidemiology and treatment of mucormycosis. Future Microbiol 2013,8(9),1163-1175 - DOI - PubMed

LinkOut - more resources